Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RESEARCH TRIANGLE PARK, N.C., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARKTM (a unique...
-
RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique...
-
During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing...
-
Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB)Company...
-
RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals, Inc. (NASDAQ:FENC) (TSX:FRX), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the...
-
SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protectionAmong the first 94 evaluable...
-
RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (TSX:FRX), (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium...